CA2139324A1 - Implanting Devices for Release of Neuroinhibitory Compounds - Google Patents
Implanting Devices for Release of Neuroinhibitory CompoundsInfo
- Publication number
- CA2139324A1 CA2139324A1 CA 2139324 CA2139324A CA2139324A1 CA 2139324 A1 CA2139324 A1 CA 2139324A1 CA 2139324 CA2139324 CA 2139324 CA 2139324 A CA2139324 A CA 2139324A CA 2139324 A1 CA2139324 A1 CA 2139324A1
- Authority
- CA
- Canada
- Prior art keywords
- release
- devices
- gaba
- neuroinhibitory
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/022—Artificial gland structures using bioreactors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/39—Pancreas; Islets of Langerhans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0012—Cell encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0613—Cells from endocrine organs
- C12N5/0614—Adrenal gland
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0687—Skull, cranium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0693—Brain, cerebrum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Abstract
Methods are disclosed for the alleviation of movement disorders via the implantation of static devices which focally release neuroinhibitory compounds to preselected brain areas. Pathological conditions to be treated by these methods include parkinsonian movement disorders, Huntington's chorea, and epileptiform seizure activity. In the treatment of parkinsonism, target areas implantation include the subthalamic nucleus, the globus pallidus internus, and the substantia nigra pars reticulata. In the treatment of epilepsy, implants may be placed in an epileptogenic focus area of neural over-activity. The devices may be polymeric implants that release neuroinhibitory compounds such as GABA, GABA agonists, GABA potentiators, action potential blockers and voltage dependent calcium channel blockers, and glutamate antagonists. Alternatively, the devices may contain living cells which secrete neuroinhibitory compounds.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/912,463 US5871472A (en) | 1987-11-17 | 1992-07-13 | Planting devices for the focal release of neuroinhibitory compounds |
US07/912,463 | 1992-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2139324A1 true CA2139324A1 (en) | 1994-01-20 |
CA2139324C CA2139324C (en) | 1998-09-29 |
Family
ID=25431969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002139324A Expired - Fee Related CA2139324C (en) | 1992-07-13 | 1993-07-12 | Implanting devices for release of neuroinhibitory compounds |
Country Status (11)
Country | Link |
---|---|
US (3) | US5871472A (en) |
EP (1) | EP0650377B1 (en) |
JP (1) | JPH07509628A (en) |
KR (1) | KR950702443A (en) |
AT (1) | ATE243035T1 (en) |
AU (1) | AU679451B2 (en) |
CA (1) | CA2139324C (en) |
DE (1) | DE69333053T2 (en) |
FI (1) | FI946125A (en) |
NO (1) | NO950112L (en) |
WO (1) | WO1994001166A1 (en) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE165977T1 (en) * | 1991-12-30 | 1998-05-15 | Neurex Corp | METHODS OF PRODUCING ANALGESIA AND ENHANCEMENT OPIATE ANALGESIA |
JPH09508553A (en) * | 1994-02-09 | 1997-09-02 | ユニヴァーシティ オブ アイオワ リサーチ ファンデーション | Human cerebral cortical nerve prosthesis |
WO1995024903A1 (en) * | 1994-03-17 | 1995-09-21 | Nanning Maple Leaf Pharmaceutical Co., Ltd. | The use of amino hydrogenated quinazoline compounds and derivatives thereof for abstaining from drug dependence |
SE519940C2 (en) * | 1994-06-03 | 2003-04-29 | Carl Dahlborn Ab | Implantable device |
US6011021A (en) * | 1996-06-17 | 2000-01-04 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
JPH10513471A (en) * | 1995-02-10 | 1998-12-22 | メドトロニック、インコーポレイテッド | Methods and devices for the administration of analgesics |
US7204848B1 (en) | 1995-03-01 | 2007-04-17 | Boston Scientific Scimed, Inc. | Longitudinally flexible expandable stent |
JPH10503964A (en) * | 1995-06-07 | 1998-04-14 | ゴア ハイブリッド テクノロジーズ,インコーポレイティド | Implantable containment device for a therapeutic device and method for loading and reloading the device therein |
US6944501B1 (en) * | 2000-04-05 | 2005-09-13 | Neurospace, Inc. | Neurostimulator involving stimulation strategies and process for using it |
US20020169485A1 (en) | 1995-10-16 | 2002-11-14 | Neuropace, Inc. | Differential neurostimulation therapy driven by physiological context |
US5707396A (en) * | 1996-04-25 | 1998-01-13 | Institute National De La Sante De La Recherche Medicale (Inserm) | Method of arresting degeneration of the substantia nigra by high frequency stimulation of subthalamic nucleus |
US6094598A (en) * | 1996-04-25 | 2000-07-25 | Medtronics, Inc. | Method of treating movement disorders by brain stimulation and drug infusion |
US5735814A (en) * | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
US5711316A (en) * | 1996-04-30 | 1998-01-27 | Medtronic, Inc. | Method of treating movement disorders by brain infusion |
US5713923A (en) * | 1996-05-13 | 1998-02-03 | Medtronic, Inc. | Techniques for treating epilepsy by brain stimulation and drug infusion |
US6027721A (en) * | 1996-05-20 | 2000-02-22 | Cytotherapeutics, Inc. | Device and method for encapsulated gene therapy |
US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
US5824662A (en) * | 1996-09-27 | 1998-10-20 | Guilford Pharmaceuticals Inc. | Treatment of global and focal ischemia using naaladase inhibitors |
IL127605A0 (en) | 1996-06-17 | 1999-10-28 | Guilford Pharm Inc | Methods of cancer treatment using naaladase inhibitors |
US6017903A (en) | 1996-09-27 | 2000-01-25 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors |
US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
US6384022B1 (en) | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
PL332413A1 (en) | 1996-09-27 | 1999-09-13 | Guilford Pharm Inc | Compositions containing inhibitors of naaladase as well as methods of treating glutamatic anomaly and influencing neuronic functions among animals |
US5962521A (en) * | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
US5800474A (en) * | 1996-11-01 | 1998-09-01 | Medtronic, Inc. | Method of controlling epilepsy by brain stimulation |
US6127520A (en) | 1997-04-15 | 2000-10-03 | Regents Of The University Of Michigan | Compositions and methods for the inhibition of neurotransmitter uptake of synaptic vesicles |
US6042579A (en) * | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US5975085A (en) * | 1997-05-01 | 1999-11-02 | Medtronic, Inc. | Method of treating schizophrenia by brain stimulation and drug infusion |
US6128537A (en) | 1997-05-01 | 2000-10-03 | Medtronic, Inc | Techniques for treating anxiety by brain stimulation and drug infusion |
US6326020B1 (en) | 1997-05-16 | 2001-12-04 | Children's Medical Center Corporation | Local anesthetic formulations |
US6110902A (en) * | 1997-06-23 | 2000-08-29 | Moehler; Hanns | Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine |
US5981209A (en) * | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
US6028216A (en) * | 1997-12-31 | 2000-02-22 | Guilford Pharmaceuticals Inc. | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives |
US6395718B1 (en) | 1998-07-06 | 2002-05-28 | Guilford Pharmaceuticals Inc. | Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors |
ES2251204T3 (en) | 1998-07-06 | 2006-04-16 | Mgi Gp, Inc. | NAALADASA INHIBITORS USEFUL AS PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS. |
US6265609B1 (en) | 1998-07-06 | 2001-07-24 | Guilford Pharmaceuticals Inc. | Thio-substituted pentanedioic acid derivatives |
US8762065B2 (en) | 1998-08-05 | 2014-06-24 | Cyberonics, Inc. | Closed-loop feedback-driven neuromodulation |
US9415222B2 (en) | 1998-08-05 | 2016-08-16 | Cyberonics, Inc. | Monitoring an epilepsy disease state with a supervisory module |
US7209787B2 (en) | 1998-08-05 | 2007-04-24 | Bioneuronics Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9375573B2 (en) | 1998-08-05 | 2016-06-28 | Cyberonics, Inc. | Systems and methods for monitoring a patient's neurological disease state |
US7324851B1 (en) | 1998-08-05 | 2008-01-29 | Neurovista Corporation | Closed-loop feedback-driven neuromodulation |
US6366813B1 (en) | 1998-08-05 | 2002-04-02 | Dilorenzo Daniel J. | Apparatus and method for closed-loop intracranical stimulation for optimal control of neurological disease |
US7747325B2 (en) | 1998-08-05 | 2010-06-29 | Neurovista Corporation | Systems and methods for monitoring a patient's neurological disease state |
US7242984B2 (en) | 1998-08-05 | 2007-07-10 | Neurovista Corporation | Apparatus and method for closed-loop intracranial stimulation for optimal control of neurological disease |
US9320900B2 (en) | 1998-08-05 | 2016-04-26 | Cyberonics, Inc. | Methods and systems for determining subject-specific parameters for a neuromodulation therapy |
US7231254B2 (en) | 1998-08-05 | 2007-06-12 | Bioneuronics Corporation | Closed-loop feedback-driven neuromodulation |
US7277758B2 (en) | 1998-08-05 | 2007-10-02 | Neurovista Corporation | Methods and systems for predicting future symptomatology in a patient suffering from a neurological or psychiatric disorder |
US9042988B2 (en) | 1998-08-05 | 2015-05-26 | Cyberonics, Inc. | Closed-loop vagus nerve stimulation |
US6444657B1 (en) | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
AU757397B2 (en) | 1999-03-03 | 2003-02-20 | Uab Research Foundation | Direct central nervous system catheter and temperature control system |
US7014624B2 (en) * | 1999-03-03 | 2006-03-21 | The Uab Research Foundation | Direct central nervous system catheter and temperature control system |
US20090047325A1 (en) * | 1999-04-30 | 2009-02-19 | Neurotrophincell Pty. Limited | Xenotransplant for cns therapy |
US20050265977A1 (en) * | 1999-04-30 | 2005-12-01 | Elliott Robert B | Xenotransplant for CNS therapy |
AU4440000A (en) * | 1999-04-30 | 2000-11-17 | Diatranz Limited | Xenotransplant for cns therapy |
CA2379052A1 (en) | 1999-08-10 | 2001-02-15 | Uab Research Foundation | Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs and naturally occurring conotoxins |
EP1202720A4 (en) * | 1999-08-10 | 2004-02-25 | Uab Research Foundation | Use of gaba agonists for treatment of spastic disorders, convulsions, and epilepsy |
US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
US6348464B1 (en) | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
US7122177B2 (en) * | 2000-01-20 | 2006-10-17 | Diabcell Pty Ltd. | Preparation and xenotransplantation of porcine islets |
US6473639B1 (en) | 2000-03-02 | 2002-10-29 | Neuropace, Inc. | Neurological event detection procedure using processed display channel based algorithms and devices incorporating these procedures |
US6466822B1 (en) | 2000-04-05 | 2002-10-15 | Neuropace, Inc. | Multimodal neurostimulator and process of using it |
US7354954B1 (en) * | 2000-08-10 | 2008-04-08 | Meythaler Jay M | Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy |
ATE553766T1 (en) * | 2000-10-17 | 2012-05-15 | Diabcell Pty Ltd | PREPARATION AND XENOTRANSPLANTATION OF ISLANDS OF LANGERHANS FROM PIGS |
US6871098B2 (en) | 2000-10-30 | 2005-03-22 | Medtronic, Inc. | Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule |
US6529774B1 (en) | 2000-11-09 | 2003-03-04 | Neuropace, Inc. | Extradural leads, neurostimulator assemblies, and processes of using them for somatosensory and brain stimulation |
US20030073608A1 (en) * | 2001-04-10 | 2003-04-17 | Woolf Nancy J. | Process for treating disease |
US20030109476A1 (en) * | 2001-08-07 | 2003-06-12 | Kmiec Eric B. | Compositions and methods for the prevention and treatment of Huntington's disease |
WO2003027270A1 (en) * | 2001-09-28 | 2003-04-03 | Diabcell Pty Limited | Growing xenotransplant material in culture |
NZ515310A (en) * | 2001-11-07 | 2004-08-27 | Diabcell Pty Ltd | Methods of treatment and delivery modes |
US20030105409A1 (en) | 2001-11-14 | 2003-06-05 | Donoghue John Philip | Neurological signal decoding |
US7280870B2 (en) * | 2002-06-04 | 2007-10-09 | Brown University Research Foundation | Optically-connected implants and related systems and methods of use |
US7212851B2 (en) * | 2002-10-24 | 2007-05-01 | Brown University Research Foundation | Microstructured arrays for cortex interaction and related methods of manufacture and use |
WO2004113516A1 (en) * | 2003-06-24 | 2004-12-29 | Diabcell Pty Limited | Porcine islets cultured with porcine sertoli cells for xenotransplantation |
US20050113744A1 (en) * | 2003-11-21 | 2005-05-26 | Cyberkinetics, Inc. | Agent delivery systems and related methods under control of biological electrical signals |
US7751877B2 (en) * | 2003-11-25 | 2010-07-06 | Braingate Co., Llc | Neural interface system with embedded id |
US7647097B2 (en) | 2003-12-29 | 2010-01-12 | Braingate Co., Llc | Transcutaneous implant |
US20050203366A1 (en) * | 2004-03-12 | 2005-09-15 | Donoghue John P. | Neurological event monitoring and therapy systems and related methods |
US20050272149A1 (en) * | 2004-06-02 | 2005-12-08 | Life & Brain Gmbh | Therapeutic delivery of adenosine into a tissue |
US8560041B2 (en) | 2004-10-04 | 2013-10-15 | Braingate Co., Llc | Biological interface system |
US20060206167A1 (en) | 2005-01-06 | 2006-09-14 | Flaherty J C | Multi-device patient ambulation system |
US7991461B2 (en) | 2005-01-06 | 2011-08-02 | Braingate Co., Llc | Patient training routine for biological interface system |
US8095209B2 (en) | 2005-01-06 | 2012-01-10 | Braingate Co., Llc | Biological interface system with gated control signal |
WO2006076175A2 (en) | 2005-01-10 | 2006-07-20 | Cyberkinetics Neurotechnology Systems, Inc. | Biological interface system with patient training apparatus |
WO2006078432A2 (en) | 2005-01-18 | 2006-07-27 | Cyberkinetics Neurotechnology Systems, Inc. | Biological interface system with automated configuration |
NZ540597A (en) * | 2005-06-08 | 2007-02-23 | Neurotrophincell Pty Ltd | A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells |
US20100023021A1 (en) * | 2005-12-27 | 2010-01-28 | Flaherty J Christopher | Biological Interface and Insertion |
US8725243B2 (en) | 2005-12-28 | 2014-05-13 | Cyberonics, Inc. | Methods and systems for recommending an appropriate pharmacological treatment to a patient for managing epilepsy and other neurological disorders |
US8868172B2 (en) | 2005-12-28 | 2014-10-21 | Cyberonics, Inc. | Methods and systems for recommending an appropriate action to a patient for managing epilepsy and other neurological disorders |
EP2034885A4 (en) | 2006-06-23 | 2010-12-01 | Neurovista Corp | Minimally invasive monitoring systems and methods |
US8295934B2 (en) | 2006-11-14 | 2012-10-23 | Neurovista Corporation | Systems and methods of reducing artifact in neurological stimulation systems |
EP2124734A2 (en) | 2007-01-25 | 2009-12-02 | NeuroVista Corporation | Methods and systems for measuring a subject's susceptibility to a seizure |
WO2008092119A2 (en) | 2007-01-25 | 2008-07-31 | Neurovista Corporation | Systems and methods for identifying a contra-ictal condition in a subject |
US8036736B2 (en) | 2007-03-21 | 2011-10-11 | Neuro Vista Corporation | Implantable systems and methods for identifying a contra-ictal condition in a subject |
US9788744B2 (en) | 2007-07-27 | 2017-10-17 | Cyberonics, Inc. | Systems for monitoring brain activity and patient advisory device |
US20090090214A1 (en) * | 2007-10-04 | 2009-04-09 | Chung Yuan Christian University | Method for forming nano-scale metal particles |
US9259591B2 (en) | 2007-12-28 | 2016-02-16 | Cyberonics, Inc. | Housing for an implantable medical device |
US20090171168A1 (en) | 2007-12-28 | 2009-07-02 | Leyde Kent W | Systems and Method for Recording Clinical Manifestations of a Seizure |
US8849390B2 (en) | 2008-12-29 | 2014-09-30 | Cyberonics, Inc. | Processing for multi-channel signals |
US8588933B2 (en) | 2009-01-09 | 2013-11-19 | Cyberonics, Inc. | Medical lead termination sleeve for implantable medical devices |
US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
US8786624B2 (en) | 2009-06-02 | 2014-07-22 | Cyberonics, Inc. | Processing for multi-channel signals |
US9643019B2 (en) | 2010-02-12 | 2017-05-09 | Cyberonics, Inc. | Neurological monitoring and alerts |
EP2668264B1 (en) | 2011-01-25 | 2017-05-31 | Elixirgen, LLC | Zscan4 as a marker for pancreatic stem cells and progenitor cells and use thereof |
US9779196B2 (en) | 2013-01-31 | 2017-10-03 | Lam Research Corporation | Segmenting a model within a plasma system |
NZ751639A (en) | 2013-03-15 | 2021-07-30 | Elixirgen Therapeutics Inc | Methods of using zscan4 for rejuvenating human cells |
CA2906851C (en) | 2013-03-15 | 2019-05-07 | The Children's Medical Center Corporation | Neosaxitoxin combination formulations for prolonged local anesthesia |
US9907496B1 (en) | 2013-06-25 | 2018-03-06 | National Technology & Engineering Solutions Of Sandia, Llc | Optoelectronic system and apparatus for connection to biological systems |
US9764122B2 (en) | 2014-07-25 | 2017-09-19 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having an occluding member |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
WO2017050803A1 (en) | 2015-09-25 | 2017-03-30 | Universität Duisburg-Essen | Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
USD802755S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4353888A (en) * | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
US4346112A (en) * | 1981-06-29 | 1982-08-24 | University Patents Inc. | Composition and method for treating patients having Parkinson's Disease |
US5017375A (en) * | 1982-11-24 | 1991-05-21 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
CA1196862A (en) * | 1983-06-01 | 1985-11-19 | Anthony M.F. Sun | Microencapsulation of living tissue and cells |
US4749620A (en) * | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
US4744933A (en) * | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
US4753635A (en) * | 1986-05-23 | 1988-06-28 | Jacqueline Sagen | Inducing analgesia by implantation of cells releasing neuroactive substances |
US4883666A (en) * | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
US5208227A (en) * | 1987-08-25 | 1993-05-04 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
US5158881A (en) * | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
US5182111A (en) * | 1987-11-17 | 1993-01-26 | Boston University Research Foundation | In vivo delivery of active factors by co-cultured cell implants |
US4892538A (en) * | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5156844A (en) * | 1987-11-17 | 1992-10-20 | Brown University Research Foundation | Neurological therapy system |
CA2062746C (en) * | 1989-06-21 | 1999-02-02 | Patrick Aebischer | Neurological therapy system |
WO1991000119A1 (en) * | 1989-06-30 | 1991-01-10 | Baxter International Inc. | Implantable device |
JP3359919B2 (en) * | 1990-05-16 | 2002-12-24 | サザン・リサーチ・インスティテュート | Controlled release dopamine and uses for stimulating nerve fiber growth |
EP0584088B1 (en) * | 1991-02-08 | 1999-10-27 | Cambridge Neuroscience Research, Inc. | Substituted guanidines and derivatives thereof as modulators of neurotransmitter release and novel methodology for identifying neurotransmitter release blockers |
US5378475A (en) * | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
ATE149361T1 (en) * | 1991-06-28 | 1997-03-15 | Univ Brown Res Found | NERVE IMPLANTATION SYSTEM |
CA2111978A1 (en) * | 1991-06-28 | 1993-01-07 | Patrick Aebischer | Renewable neural implant device and method |
US5212167A (en) * | 1991-09-12 | 1993-05-18 | Trustees Of Boston University | Modulation of receptor-mediated ion transport |
-
1992
- 1992-07-13 US US07/912,463 patent/US5871472A/en not_active Expired - Lifetime
-
1993
- 1993-07-12 CA CA002139324A patent/CA2139324C/en not_active Expired - Fee Related
- 1993-07-12 WO PCT/US1993/006512 patent/WO1994001166A1/en active IP Right Grant
- 1993-07-12 EP EP93917095A patent/EP0650377B1/en not_active Expired - Lifetime
- 1993-07-12 AT AT93917095T patent/ATE243035T1/en not_active IP Right Cessation
- 1993-07-12 JP JP6503553A patent/JPH07509628A/en not_active Ceased
- 1993-07-12 DE DE69333053T patent/DE69333053T2/en not_active Expired - Lifetime
- 1993-07-12 AU AU46891/93A patent/AU679451B2/en not_active Ceased
- 1993-12-16 US US08/168,858 patent/US5474547A/en not_active Expired - Lifetime
-
1994
- 1994-07-12 KR KR1019950700120A patent/KR950702443A/en not_active Application Discontinuation
- 1994-12-28 FI FI946125A patent/FI946125A/en unknown
-
1995
- 1995-01-11 NO NO950112A patent/NO950112L/en not_active Application Discontinuation
- 1995-06-05 US US08/461,301 patent/US5573528A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
FI946125A0 (en) | 1994-12-28 |
EP0650377B1 (en) | 2003-06-18 |
AU679451B2 (en) | 1997-07-03 |
AU4689193A (en) | 1994-01-31 |
JPH07509628A (en) | 1995-10-26 |
EP0650377A1 (en) | 1995-05-03 |
NO950112D0 (en) | 1995-01-11 |
WO1994001166A1 (en) | 1994-01-20 |
US5474547A (en) | 1995-12-12 |
CA2139324C (en) | 1998-09-29 |
US5573528A (en) | 1996-11-12 |
EP0650377A4 (en) | 1997-05-21 |
NO950112L (en) | 1995-01-11 |
US5871472A (en) | 1999-02-16 |
KR950702443A (en) | 1995-07-29 |
ATE243035T1 (en) | 2003-07-15 |
DE69333053T2 (en) | 2004-05-06 |
DE69333053D1 (en) | 2003-07-24 |
FI946125A (en) | 1995-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2139324A1 (en) | Implanting Devices for Release of Neuroinhibitory Compounds | |
ES2088863T3 (en) | SYSTEM OF CONTROLLED ADMINISTRATION OF DRUGS FOR TREATMENT OF NERVOUS DISORDERS. | |
Strauss et al. | Where are we with surgical therapies for Parkinson's disease? | |
US20080243204A1 (en) | Variational parameter neurostimulation paradigm for treatment of neurologic disease | |
WO1994001166A9 (en) | Implanting devices for release of neuroinhibitory compounds | |
DE102007003799A1 (en) | Implant for stimulation of nerve cells | |
WO2005025293A3 (en) | Fused ring heterocycles as potassium channel modulators | |
JP2002544234A5 (en) | ||
Krauss et al. | Cerebellar and thalamic stimulation treatment for epilepsy | |
Hu et al. | Role of deep brain stimulation in modulating memory formation and recall | |
US10279173B2 (en) | Overvoltage protection circuitry | |
Wyckhuys et al. | Deep brain stimulation for epilepsy: knowledge gained from experimental animal models | |
Gildenberg | Neuromodulation: a historical perspective | |
EP1790379B1 (en) | Retina implant for electrical stimulation of the retina | |
Park | The bionic eye: retinal prostheses | |
Green et al. | Deep brain stimulation | |
Butler et al. | History of the therapeutic use of electricity on the brain and the development of deep brain stimulation | |
Micera et al. | Guest editorial interfacing with the peripheral nervous system to develop innovative neuroprostheses | |
Wu et al. | From Bioelectronics to Nanobioelectronics: The Biomedical Electronics Translational Research Center [Highlights] | |
Huang et al. | Developmental history of neurorestoratology | |
van Boekholdt | Unraveling the role of peripheral nerve stimulation in tDCS memory enhancement in a novel rat model | |
Gurwell et al. | Programming Deep Brain Stimulation in the globus pallidus internus for treatment of idiopathic Parkinson's disease: experience at the University of Kentucky | |
Hamani et al. | Special lecture: Brain stimulation: Perspectives for the future | |
Xia et al. | MEMS-based system and image processing strategy for epiretinal prosthesis | |
Matsumoto et al. | Neurostimulation for epilepsy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |